Quick answer
How do AOD-9604 and retatrutide differ as research compounds? They share almost nothing beyond a use in metabolic research. AOD-9604 is a 16-residue fragment modeled on the C-terminal region of growth hormone, with one disulfide bond and no receptor-agonist design. Retatrutide (LY3437943) is a 39-residue engineered agonist that activates three class B receptors at once: GIP, GLP-1 and glucagon. They differ in size, in target, in the models in which they have been described, and in the questions a laboratory can ask with them, so they are complements for different experiments rather than alternatives.
Comparison articles often line up compounds as if they competed for the same job. Here the more useful comparison is of the experiment each one makes possible. This article sets out the structural facts from the V8 product pages, the receptor biology behind each, the preclinical models in which each has been described, and the practical handling differences. For laboratory research use only; not for human consumption.
Side-by-side summary
| Feature | AOD-9604 | Retatrutide |
|---|---|---|
| Design basis | Fragment of human growth hormone (176–191 region) | Engineered multi-receptor agonist peptide (code LY3437943) |
| Length | 16 amino acids | 39 amino acids |
| Primary target in research | Lipolytic signaling in adipocyte and rodent models; no reported IGF-1 effect | GIP, GLP-1 and glucagon receptors |
| Receptor class | Not a defined class B receptor agonist | Class B G-protein-coupled receptors |
| Disulfide bond | One (Cys7–Cys14) | None reported on the product page |
| Supplied by V8 as | 5 mg lyophilized powder | 10 mg and 20 mg lyophilized powder |
| Storage on product page | 2–8 °C; −20 °C long term; protect from heat, moisture, light | Same |
Specifications come from the AOD-9604 product page and the retatrutide product page; both list a ≥98% purity specification.
Two different kinds of molecule
AOD-9604 is a piece of a natural protein. Its research rationale, set out by Ng and colleagues (2000) and Heffernan and colleagues (2001), was to isolate the portion of growth hormone associated with lipid metabolism in rodent models and examine it apart from the rest of the hormone. The sequence is short, linear apart from one ring, and its structure is described residue by residue in the AOD-9604 peptide explained.
Retatrutide is a designed analogue. It belongs to the family of incretin-based peptides, built on a native hormone scaffold and modified so that one molecule engages three receptors. The discovery and preclinical characterization were reported by Coskun and colleagues (2022). The biology of the receptors themselves is reviewed by Campbell and Drucker (2013). The contrast is basic: one compound is a truncated natural sequence, the other an engineered ligand with deliberate pharmacology at three targets.
Targets and the questions they allow
| Research question | Better matched to | Why |
|---|---|---|
| What does the C-terminal region of growth hormone do on its own? | AOD-9604 | It isolates that region from the 191-residue parent |
| How do three incretin-family receptors cooperate in one cell system? | Retatrutide | A single ligand engages GIP, GLP-1 and glucagon receptors |
| Is a signal independent of IGF-1? | AOD-9604 | Published work describes lipolytic signaling without an IGF-1 effect in the models used |
| Receptor-binding and cAMP assays in transfected cells | Retatrutide | Defined GPCR targets support potency and selectivity comparison |
| Disulfide-ring stability studies | AOD-9604 | A single, well-defined disulfide |
A multi-receptor agonist forces the question of which receptor is responsible for an observed effect. Experiments typically answer it with receptor-selective antagonists, receptor-knockout models or cells that express only one receptor. The comparison between the triple agonist and a dual agonist is discussed in retatrutide versus tirzepatide, and the receptor background is in incretin receptors explained.
What each literature actually reports
The AOD-9604 literature consists mainly of early rodent and adipocyte studies from the 2000s. Heffernan and colleagues (2001) compared the fragment with the full hormone in obese mice and reported effects on fat oxidation in that model. Those are animal findings from one research program and should be read as such. The retatrutide preclinical literature reports receptor pharmacology and rodent studies in the Coskun paper cited above, and it is far more recent. In both cases the sensible approach is to cite what a given study measured, in which system, and not to generalize across species or compounds. A broader discussion of the compound is in the retatrutide research overview and the AOD-9604 research overview.
Readouts and model systems compared
Because the two compounds act through different mechanisms, their readouts barely overlap. The table lists the endpoints that have typically been paired with each in published preclinical work; it describes assay design, not outcomes.
| Readout | AOD-9604 context | Retatrutide context |
|---|---|---|
| Glycerol or free-fatty-acid release | Primary adipocyte lipolysis endpoint | Secondary, usually downstream of receptor signaling |
| cAMP accumulation in receptor-expressing cells | Not a standard endpoint | Standard potency endpoint for each of the three receptors |
| Receptor-binding competition | Not applicable to a defined receptor | Used to rank affinity at GIP, GLP-1 and glucagon receptors |
| Rodent energy-balance studies | Reported in the early obese-mouse work | Reported in the preclinical characterization |
| Chemical stability (HPLC, mass) | Focus on disulfide integrity | Focus on aggregation and adsorption |
Two consequences follow. First, a result obtained with one compound cannot be used as a positive control for the other, since the signaling cascades are different. Second, the controls differ: an AOD-9604 experiment benefits from a reduced or scrambled-sequence peptide control that tests whether the ring structure matters, while a retatrutide experiment benefits from receptor-selective antagonists or single-receptor cell lines that show which of the three targets is responsible for a signal.
Common mistakes when comparing the two
- Comparing mass instead of molarity. A 16-residue and a 39-residue peptide with the same milligram amount contain very different numbers of molecules. Convert to molar concentration using each molecular weight before comparing anything.
- Importing assay conditions. Buffer, pH, vessel and diluent that suit one peptide may not suit the other.
- Equating a rodent result with a cell result. Whole-animal studies integrate many tissues; cell assays isolate one. Label which level each cited result sits at.
- Skipping lot documentation. Purity and identity data differ between lots and between compounds; record each separately.
Handling differences that affect experiments
Both products are lyophilized powders with the same storage instruction. The practical differences come from the molecules. AOD-9604's disulfide makes it sensitive to reducing agents and alkaline buffers. The 39-residue retatrutide chain is larger and more prone to adsorption and aggregation at low concentration; the handling side is covered in retatrutide reconstitution and handling and retatrutide storage and stability.
Concentration arithmetic is identical in form for both compounds: peptide mass divided by final solution volume. The 5 mg AOD-9604 vial, the 10 mg and the 20 mg retatrutide vials give different results from the same volume, which is why the reconstitution calculator should be used for each lot rather than reusing numbers between compounds. Do not carry assumptions about solvent, vessel or storage time from one compound to the other without a stability check.
Can they be used in the same study?
A study could include both compounds, for example as a pathway comparison in the same adipocyte model. The design rules are those of any multi-compound experiment: each compound alone, vehicle controls with identical diluent, a pre-specified reference model if mixtures are used (Chou, 2006), and independent biological replicates. Keep the compounds in separate vials unless a stability check has shown the mixture to be compatible. General blend reasoning is in peptide blends and research stacks.
Reading the documents
For each lot, compare the certificate, where one is published in the COA library, with the product-page specification. The retatrutide page lists lot-level certificates for its 10 mg and 20 mg sizes; the AOD-9604 page shows its certificate as in progress at the time of writing, so check the page for the current status instead of assuming. Quality principles for peptide materials are summarized by Vergote and colleagues (2009), and understanding HPLC purity explains the limits of a single purity percentage. Other compounds are listed in the catalog.
Frequently asked questions
Are AOD-9604 and retatrutide related compounds?
No. AOD-9604 is a fragment modeled on the C-terminal region of growth hormone, while retatrutide is an engineered peptide that activates the GIP, GLP-1 and glucagon receptors. They have different structures, targets and literature.
How many amino acids does each have?
AOD-9604 has 16 residues and retatrutide has 39. This size difference affects solubility, adsorption and analytical behavior.
Which one is a receptor agonist?
Retatrutide is designed as a triple agonist of class B receptors. AOD-9604 is described in the literature through lipolytic signaling in rodent and adipocyte models and is not defined as an agonist of these receptors.
Does AOD-9604 contain a disulfide bond?
Yes, one bond between its two cysteines. That bond makes it sensitive to reducing agents and alkaline buffers.
Which compound suits an IGF-1-independence question?
Published work on AOD-9604 describes lipolytic signaling without an IGF-1 effect in the models used, so it is the one that has been framed around that question.
Can both compounds share one vial?
They should be kept separate unless a stability check shows the mixture is compatible in the chosen diluent. Time-course HPLC of the mixture against single-component controls is the standard test.
Do the vial sizes affect concentration math?
Yes. The formula is peptide mass divided by final solution volume, so the 5 mg AOD-9604 vial and the 10 or 20 mg retatrutide vials give different concentrations from the same volume. Use the calculator for each lot.
Are the storage instructions the same?
Both product pages list refrigeration at 2–8 °C, −20 °C for long-term storage and protection from heat, moisture and light.
Why compare by molarity and not by milligrams?
A 16-residue and a 39-residue peptide of the same mass contain different numbers of molecules. Converting each to molar concentration with its own molecular weight makes the comparison meaningful across the two compounds and across published studies that report in different units.
What controls suit an AOD-9604 experiment?
A reduced or scrambled-sequence peptide control tests whether the disulfide ring matters, alongside a vehicle control with the same diluent in every arm.
Do the findings from one compound apply to the other?
No. The studies used different systems and measured different endpoints, so results should be cited for the compound and model in which they were obtained.
Related reading: AOD-9604: Fragment Design and Lipolysis Research, AOD-9604 Amino Acid Sequence and Chemical Structure, AOD-9604 Compatibility and Combination Study Design.
References
- Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053183
- Heffernan M, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. doi:10.1016/j.cmet.2022.07.013
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837. doi:10.1016/j.cmet.2013.04.008
- Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681. doi:10.1124/pr.58.3.10
- Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. doi:10.1002/psc.1167
